STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.

doi:10.2217/fon-2021-1486

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma.

Future oncology (London, England) - 1 Jun 2022

Schadendorf Dirk, Dummer Reinhard, Robert Caroline, Ribas Antoni, Sullivan Ryan J, Panella Timothy, McKean Meredith, Santos Edgardo S, Brill Kimberli, Polli Anna, Pietro Alessandra di, Ascierto Paolo A

Abstract excerpt

Despite the significant progress in the treatment of unresectable or metastatic BRAF V600-mutant melanoma, there remains two primary treatment options: targeted therapy and immunotherapy. Targeted therapy or immunotherapy alone is associated with efficacy limitations including efficacy limited to select patient subsets. With separate mechanisms of action and different response patterns, the combination of...

Read the complete abstract on PubMed